Evolution of the Functional Profile of HIV-Specific CD8+ T cells in a Cohort of Long Term Nonprogressors M López, N Rallón, A Peris, M Salgado, B Rodés,

Slides:



Advertisements
Similar presentations
“ The therapeutic effect of FIT- 06, GTU®-Multi-HIVB DNA vaccine, observed in HIV-1 infected people. Results of a Phase II trial”. Prof. Mart Ustav SVP,
Advertisements

Vaccine potential of dendritic cells pulsed with autologous virus in anti-HIV immune response Prof. Dr. Alberto José da Silva Duarte DERMATOLOGY DEPARTMENT.
Virologic and immunologic response following antiretroviral therapy initiation among pregnant and postpartum women with acute HIV-1 infection: MOPDB0101.
Polyclonality & Initial HIV- specific CD4 clone size determine outcome of infection Hester Korthals Altes Lab. Immunologie Tissulaire et Cellulaire Hôpital.
High Affinity HIV-1 Specific CTL Become Exhausted in Early HIV-1 Infection High Affinity HIV-1 Specific CTL Become Exhausted in Early HIV-1 Infection Abstract.
Protective HLA Class I alleles are associated with reduced immune activation in Primary HIV infection Elizabeth Hamlyn 1, Stephen Hickling 2, Abdel Babiker.
Lecture: HIV I.Motivation What can we learn when we apply evolutionary principles to our understanding of the of the HIV epidemic?? Can we use HIV to introduce.
31 subjects with sufficient viable cells studied for T cell and MAIT cell phenotype * One subject was excluded from CD38+HLA-DR+ T cell analysis 30 subjects.
Introduction to Basic Science of HIV/AIDS. BREAKDOWN OF HIV RESEARCH BASIC SCIENCEBASIC SCIENCE Seeks the fundamental understanding of the biological,
Immunology of HPV Infection Craig Woodworth Department of Biology Clarkson University Potsdam, NY.
Materials and Methods Abstract Conclusions Introduction 1. Korber B, et al. Br Med Bull 2001; 58: Rambaut A, et al. Nat. Rev. Genet. 2004; 5:
Norma I. Rallón 1, José Medrano 1, Salvador Resino 2, Clara Restrepo 1, Vincent Soriano 1 and José M. Benito 1 1 Department of Infectious Diseases, Hospital.
Cell- and Tissue-based Measures of Viral Persistence Are Associated with Immune Activation and PD-1-Expressing CD4+ T cells H Hatano 1, V Jain 1, PW Hunt.
DNA methylation as an epigenetic marker in HIV-2 disease in West Africa? Alberta Davis MRC Laboratories, Gambia 18th January 2013.
Novel strategies for prevention and treatment of HIV infection Prasit Faipenkhong Pairoaj Vonghathaipaisarn Rodjana Chunhabundit Zhang Jianjun.
Eric S. Rosenberg, M.D. Associate Professor of Medicine Massachusetts General Hospital Harvard Medical School
Immune correlates of unusual control of viral replication after cessation of HAART Ellen Van Gulck 1, Leo Heyndrickx 1, Céline Merlin 1, Sandra Coppens.
Long-term ART initiated during primary HIV-1 infection limits the HIV-1 reservoir size but not to levels found in LTNPs Eva Malatinkova, Ward De Spiegelaere,
Safety and effect of an extract from Ganoderma lucidum (Reishi) on NK cell numbers in HIV+ individuals not taking antiretroviral therapy. JT Leonard 1,
Background There is uncertainty regarding the frequency, predictors, and outcomes of IRIS events Prior studies on IRIS have been limited to convenience.
Detection of Immune Responses in Mucosal T-cells in Kenya Jackton Indangasi 2, Hannah Cheeseman 1, Onyango J. I. Obila 2, Simon Ogola 2, Robert Langat.
Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection DR. S.K CHATURVEDI DR. KANUPRIYA CHATURVEDI.
Non-Infectious Papilloma virus–like Particles (VLPs) inhibit HIV-1 replication: Implications for immune control of HIV-1 replication by IL-27. Laboratory.
HIV-1 infected subjects treated with an autologous dendritic cell therapy (AGS-004), exhibited a significant reduction in viral load (when compared to.
Impact of Raltegravir on Immune Reconstitution and Thymopoiesis in HIV-1 Infected Patients with Undetectable Viremia Carolina Garrido, N Rallón, N Zahonero,
I. Jean Davis, PhD, PA, AAHIVS Manager - Clinical Services Desert AIDS Project.
Persistent HIV-1 infection in duodenal mucosa and memory CD8+ T cell differentiation Liliana Belmonte 1 PhD; Alberto Zalar 2 MD; Patricia Baré 1 PhD; Noel.
Switch to LPV/r monotherapy  Pilot LPV/r  M  LPV/r Mono  KalMo  OK  OK04  KALESOLO  MOST  HIV-NAT 077.
Immune Discordance on Highly Active Antiretroviral Therapy Can Still be Regarded as a Therapeutic Success Nur F. Önen MD, MRCP 1, Rachel Presti MD PhD.
Simplification from Protease Inhibitors to Once or Twice Daily Raltegravir: the ODIS trial Eugenia Vispo, Pablo Barreiro, Francisco Blanco, Sonia Rodríguez-Novoa*,
Results Compliance with Breast Cancer Screening Guidelines in the HIV Clinic: A Quality Improvement Tool E. Patrozou M.D., E. Christaki M.D., L. Hicks.
HIV-1 infection decreases CD127 and PD1 expression on duodenal CD8+T cells Liliana Belmonte, PhD Academia Nacional de Medicina Buenos Aires, Argentina.
Diversity and Divergence in HIV-1 Viral Variants between patients with high CD4+ T Cell Variability and Patients with Rapid CD4+ T Cell Decline Kevin Paiz-Ramirez.
Progressive histological liver improvement after sustained virological response to therapy in HCV / HIV coinfected patients. Jose L. Casado,
Persistent immune activation despite suppressive HAART is associated with higher risk for viral blips in HIV-1 infected individuals Alexander Zoufaly 1.
Chelsea Harmon Catherine Hanson Abby Llaneza Jen Williams
Distinct hepatitis C virus kinetics in HIV- infected patients treated with ribavirin plus either pegylated interferon α-2a or α-2b Eugenia Vispo, Pablo.
Regulatory T cell abnormalities associated with aberrant CD4+ T-cell responses in HIV+ patients with immune reconstitution disease (IRD) Nabila SEDDIKI.
Study Design UIHC HIV Clinic Patients Invitation – Informed Consent Heparinized Blood/Serum Obtained CD4, HIV VL measured Serum => GBV-C VL Cells => flow.
Strategies for Management of Antiretroviral Therapy Study Wafaa El-Sadr and James Neaton for the SMART Study Team.
T-cell activation positively correlates with cell-associated HIV-DNA level in PBMCs in viremic patients with acute or chronic HIV-1 infection Laurence.
Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Immune reconstitution Anjie Zhen, PhD
Conclusions Materials and Methods Background Objectives HIV-1 RNA is the most significant determinant of cervical HIV-1 shedding. Shedding has also been.
HUMAN IMMUNODEFICIENCY VIRUS AND ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
CATEGORY: VACCINES & THERAPEUTICS HIV-1 Vaccines Shokouh Makvandi-Nejad, University of Oxford, UK HIV-1 Vaccines © The copyright for this work resides.
Date of download: 5/30/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Influence of the Timing of Antiretroviral Therapy.
Cellular immune control of Human Immunodeficiency Virus (HIV) Dr. Ali Jalil Ali College of pharmacy.
Response to Antiretroviral Treatment In an Ethiopian Hospital Samuel Hailemariam, MD, MPH; J Allen McCutchan, MD, MSc Meaza Demissie, MD, PMH, PHD; Alemayehu.
HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.
CD4 trajectory among HIV positive patients receiving HAART in a large East African HIV care centre Agnes N. Kiragga 1, Beverly Musick 2 Ronald Bosch, Ann.
Background  HIV-1 infection persists in reservoirs and leads to progressive depletion of CD4+ T-cells even in subjects with slow disease progression 
Date of download: 7/6/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effect of Antiretroviral Therapy on Viral Load, CD4.
The Dynamics of HIV RNA, CD4+ Count and Mycobacterium tuberculosis (Mtb) Antigen Specific Cytokines in TB/HIV Patients Following Successful Tuberculosis.
Expression Analysis of α4 integrin and related genetic polymorphisms in HIV acquisition and disease progression OF infected individuals Livia R. GóeS 1,
HIV-1 Vaccines Shokouh Makvandi-Nejad, University of Oxford, UK
Seroprevalence, prevalence, type and factors associated with HPV infection at multiple sites in young HIV-positive MSM On behalf of the HPV MAPS Research.
Stability of whole blood over time for CD4 & Viral load determination in HIV infected persons. N. Sippy & A. Abayomi Ladymeade Reference Unit Laboratory.
Catherine K. Koofhethile 21st IAS July,2016 Durban, SA
Higher rate of antiretroviral therapy reinitiation among HIV-HBV coinfected patients in the episodic arm of the SMART study Dore G.1, Soriano V.2, Neuhaus.
Jeopardy Game Hosted by PHDP Jamaica MODULE 4 Treatment Literacy.
Molecular Therapy - Methods & Clinical Development
Table 2. Mean intrasubject diversity for the 11 study participants, by genomic region. From: Hepatitis C Virus (HCV) Diversity in HIV-HCV-Coinfected Subjects.
Figure 2 Systemic immune responses to cryptococcal antigen
Influence of hepatitis C and hepatitis G virus co-infection on viral and cellular dynamics in patients infected with human immunodeficiency virus following.
Dorina Onoya1, Tembeka Sineke1, Alana Brennan1,2, Matt Fox1,2
The protective compared to other B. Rodés,
Human Immunodeficiency Virus Controllers: Mechanisms of Durable Virus Control in the Absence of Antiretroviral Therapy  Steven G. Deeks, Bruce D. Walker 
Management and Development for Health (MDH)
Public Health Implications
Presentation transcript:

Evolution of the Functional Profile of HIV-Specific CD8+ T cells in a Cohort of Long Term Nonprogressors M López, N Rallón, A Peris, M Salgado, B Rodés, V Soriano, J González-Lahoz, and JM Benito Hospital Carlos III, Madrid, Spain

A small proportion of HIV-subjects is able to control virus replication and halt disease progression A small proportion of HIV-subjects is able to control virus replication and halt disease progression A higher and/or better HIV-specific immune response in these patients is believed to contribute to their favourable outcome A higher and/or better HIV-specific immune response in these patients is believed to contribute to their favourable outcome However, it is not well understood what characteristics of HIV-specific immune response better correlate with protection However, it is not well understood what characteristics of HIV-specific immune response better correlate with protection

Transversal studies have suggested that a polyfunctional HIV-specific immune response and directed against Gag may be involved in the control of HIV viral replication Transversal studies have suggested that a polyfunctional HIV-specific immune response and directed against Gag may be involved in the control of HIV viral replication

Nat Med Jan;13(1):46-53Blood Jun 15;107(12):4781-9

The stability or the potential evolution over time of cellular immune response in the absence of antiretroviral therapy, especially in long term non-progressors (LTNP) has been scarcely analysed

Herein, we have studied the evolution of HIV specific CD8+ T cell response in LTNP followed for four years OBJECTIVE

10 HIV+ patients belonging to a cohort of well- characterized LTNP followed for four years were included in this study 10 HIV+ patients belonging to a cohort of well- characterized LTNP followed for four years were included in this study LTNP : LTNP : Serologically proven HIV-1 infection lasting for over 10 years, Serologically proven HIV-1 infection lasting for over 10 years, CD4 counts always above 500 cells/  l and CD4 counts always above 500 cells/  l and lack of HIV-related symptoms in the absence of any antiretroviral therapy lack of HIV-related symptoms in the absence of any antiretroviral therapy METHODOLOGY

Three functions of CD8+ T-cells (production of MIP1 , IL2 and TNF  ) were simultaneously examined in response to HIV-Gag and Nef peptide-pools using multiparameter flow cytometry Three functions of CD8+ T-cells (production of MIP1 , IL2 and TNF  ) were simultaneously examined in response to HIV-Gag and Nef peptide-pools using multiparameter flow cytometry

LTNP P A Gag-specific CD8+ T cell responses MIP1β CD8- ECD TNF α - PECY7 IL2-PE SS FS MIP1β LymphocytesCD8+ cells

All variables were expressed as median [interquartile range] All variables were expressed as median [interquartile range] Differences between values at baseline and after four years were evaluated using non- parametric tests Differences between values at baseline and after four years were evaluated using non- parametric tests

RESULTS

n CD4 count (cell/  l) Viral Load (Log ARN copies / ml) At baseline 10 After 4 years of follow up n.s 619[300]3.2[1.6]10 p n.s n.s: no significant difference, p>0,05 754[400] 2.6[0.8] Characteristics of Patients

HIV- GAG SPECIFIC CD8+ T CELL RESPONSE

After 4 years After 4 years of follow up of follow up % CD8+ T cells At baseline At baseline * p< After 4 years After 4 years of follow up of follow up % CD8+ T cells At baseline At baseline * p< Global HIV-GAG specific CD8+ T cell response in LTNPs at baseline and after 4 years of follow up

MIPβ TNFα IL2 At baseline At baseline After 4 years After 4 years of follow up of follow up Percentage of patients Prevalence of HIV-Gag CD8+ T cell response in LTNPs at baseline and after 4 years of follow up

MIPβ TNFα IL2 % CD8+ T cells At baseline At baseline After 4 years After 4 years of follow up of follow up * * * p<0.05 Levels of seven different functional subsets of CD8+ T cells in response to HIV-GAG in LTNPs at baseline and after 4 years of follow up

Contribution of seven different functional subsets of CD8+ T cells to the global HIV-GAG response in LTNPs at baseline and after 4 years of follow up

Contribution of seven different functional subsets of CD8+ T cells to the global HIV-GAG response in each LTNP at baseline and after 4 years of follow up

HIV- NEF SPECIFIC CD8+ T CELL RESPONSE

% CD8+ T cells At baseline At baseline After 4 years After 4 years of follow up of follow up * p<0.05 Global HIV-NEF specific CD8+ T cell response in LTNPs at baseline and after 4 years of follow up

Prevalence of HIV-Nef CD8+ T cell response in LTNPs at baseline and after 4 years of follow up

Levels of seven different functional subsets of CD8+ T cells in response to HIV-Nef in LTNPs at baseline and after 4 years of follow up

Contribution of seven different functional subsets of CD8+ T cells to the global HIV-NEF response in LTNPs at baseline and after 4 years of follow up

Contribution of seven different functional subsets of CD8+ T cells to the global HIV-NEF response in each LTNP at baseline and after 4 years of follow up

HIV-specific CD8+ responses are maintained over time in LTNP. The functional profile of this response may evolve in a different manner depending on the targeted HIV protein. Functionality of Gag specific CD8+ T cells tends to increase over time, highlighting its importance in controlling HIV replication. CONCLUSIONS

Patients ACKNOWLEDGMENTS Laboratory Immunology Group Mariola López Sara Lozano Norma Ibon Rallón Alejandra Peris Clara Restrepo Jose Miguel Benito To all staff at the Molecular Biology Lab Clinic Juan González-Lahoz Pablo Labarga Pablo Barreiro Francisco Blanco Luz Martín-Carbonero Pablo Rivas Eugenia Vispo Jose Medrano Vicente Soriano Funding